Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

FHS
July 23, 2024
9:04 am

The advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control.

Cybin Reports Positive Topline Data From Phase 2 Study Of CYB003 in Major Depressive Disorder

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN), one of the leading public psychedelic biotech drug developers, released full CYB003 Phase 2 trial results for Major Depressive Disorder (MDD).

November 30, 2023

Low-molecular weight human interleukin-1β antagonist discovered

Researchers described the detection of a human interleukin-1β antagonist with low molecular weight that disrupts interactions with the interleukin-1 receptor type I receptor.

September 11, 2023

Acon receives first FDA clearance for over-the-counter COVID-19 antigen test

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The Food and Drug Administration

November 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.